Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3480 for Cognitive Deficits in Schizophrenia (HALO)
NCT00528905Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2007
- Primary completion
- Oct 2008
- Countries
- 2
01
Overview
A Phase 2 trial of ispronicline in schizophrenia, sponsored by AstraZeneca. Started Aug 2007; status: completed.
02
Drugs
ispronicline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00528905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00528905.